Loading…
LEXX
Lexaria Bioscience Corp.
NASDAQ· Healthcare· Biotechnology· CUSIP 52886N406
$10.35-11.39%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $17.1M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$5.10
- ROE
- -162.77%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.37
- 52-week high
- $23.25
- 52-week low
- $4.21
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -96.5% over 5Y.
today you would have $34.93▼ -96.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $9.26 | $31.50 | $18.75 | $36.90 | $60.45 | |
| P/S | 56.8x | 19.4x | 78.9x | 56.8x | 57.3x | 31.9x |
| P/B | 4.2x | 4.6x | 4.6x | 4.2x | 1.8x | 1.7x |
| EPS | -$9.90 | -$7.05 | -$15.15 | — | -$14.25 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HKPDCellyan Biotechnology Co., Ltd | $0.35 | — | 0.9x | — | -15.59% | $16.84M |
| BCDABioCardia, Inc. | $1.15 | — | 6.4x | — | -1803.19% | $17.41M |
| PLSMPulsenmore Ltd. | $2.57 | — | — | — | -17.62% | $16.71M |
| TPSTTempest Therapeutics, Inc. | $1.06 |
About the company
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
- 7
- Kelowna, Canada
Company description provided by Yahoo Finance.